)
Visual
test
Stoke Therapeutics
Stoke Therapeutics (STOK) investor relations material
Stoke Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary16 Mar, 2026
Executive summary
Achieved $184.4 million in revenue for 2025, driven by new Biogen collaboration and ongoing Acadia partnership.
Lead candidate zorevunersen advanced to global Phase 3 EMPEROR trial for Dravet syndrome; first patient dosed in August 2025.
STK-002 for ADOA entered Phase 1 OSPREY study in February 2026.
Ended 2025 with $390.9 million in cash, cash equivalents, and marketable securities, funding operations into 2028.
Financial highlights
Revenue increased to $184.4 million in 2025 from $36.6 million in 2024, mainly due to Biogen upfront and development payments.
Research and development expenses rose to $137.9 million (from $89.1 million in 2024), reflecting increased clinical activity.
Sales, general and administrative expenses were $67.1 million, up from $48.8 million in 2024.
Net loss narrowed to $6.9 million in 2025 from $89.0 million in 2024.
Accumulated deficit at year-end was $497.7 million.
Outlook and guidance
Cash runway expected to fund operations into 2028.
Phase 3 EMPEROR trial for zorevunersen to complete enrollment in Q2 2026, with pivotal data anticipated mid-2027.
Rolling NDA submission for zorevunersen planned for first half of 2027.
OSPREY Phase 1 study for STK-002 actively recruiting in Europe.
Phase 3 EMPEROR enrollment and NDA timing
Impact of Acadia program terminations on SYNGAP1
Waltham lease and R&D spend impact on runway
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Stoke Therapeutics
- Phase III Dravet study nears enrollment completion, with strong efficacy and market positioning.STOK
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Four-year data show durable seizure reduction and cognitive gains, with phase 3 readout in 2027.STOKGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- Global phase III for Dravet syndrome advances, with robust efficacy and cognitive data supporting design.STOKTD Cowen Genetic Medicines & RNA Summit3 Feb 2026
- Zorevunersen delivers sustained seizure and cognitive improvements in Dravet syndrome, with phase III plans advancing.STOKGoldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
- Zorevunersen delivers durable seizure and cognitive gains in Dravet, with phase III set for next year.STOKH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Lead candidate shows 80% seizure reduction and cognitive gains in Dravet, with pivotal trial plans underway.STOK2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026
- Phase III for Dravet therapy nears full enrollment, with durable efficacy and global expansion plans.STOK44th Annual J.P. Morgan Healthcare Conference14 Jan 2026
- RNA therapy for Dravet syndrome shows strong seizure and cognitive benefits, with Phase 3 underway.STOKJefferies London Healthcare Conference 202413 Jan 2026
- Zorevunersen delivers durable seizure and cognitive improvements, addressing key unmet needs.STOKStatus Update11 Jan 2026
Next Stoke Therapeutics earnings date
Q1 20268 May, 2026
Stoke Therapeutics
Next Stoke Therapeutics earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage